Stepan earnings release, July 29, 2026
Stepan Reports Second Quarter 2026 Results
Northbrook, Illinois, July 29, 2026 — Stepan Company (NYSE: SCL) today reported:
Second Quarter 2026 Highlights
First Half 2026 Highlights¹
“Quarterly earnings were up significantly driven by improved Surfactant and Polymer results. Second quarter adjusted EBITDA of $74.4 million was up 45% year-over-year due to global volume growth, margin recovery and Project Catalyst savings. We believe the quarter also benefited from customer pre-buys as a result of the global geopolitical situation. Surfactant and Polymer adjusted EBITDA were up 59% and 22%, respectively,” said Luis E. Rojo, President and Chief Executive Officer. “Surfactant organic sales volume was up 7% and Polymer sales volume was up 5% in the quarter. The Surfactant volume growth was broad-based and across all end markets and all regions. Within Polymers, the North American Rigid and Phthalic Anhydride businesses delivered double digit volume growth. We are pleased with the growth we achieved in several of our key strategic end markets despite ongoing global economic uncertainties and supply chain disruptions. We continue to execute Project Catalyst safely and in line with expectations. As part of the organizational-effectiveness component of Project Catalyst, today we announced a plan to reduce the Company’s global salaried workforce by around 100 roles before the end of the year. During the past few quarters, we took a disciplined and deliberate approach to minimize the impact of these actions through normal attrition, pausing external hiring and emphasizing internal talent. We are committed to supporting our affected colleagues through this transition in line with our People
First culture.”
Financial Summary
Percentage Change in Net Sales
Net sales in the second quarter of 2026 increased 15% year-over-year. This increase reflects higher selling prices, mainly attributable to the pass-through of higher raw material costs and more favorable product mix, a 3% increase in sales volume and the favorable impact of foreign currency translation. Organic sales volume was up 6% year-over-year.²
Segment Results
Consolidated adjusted EBITDA
Financial statements
Income Statement
Three Months Ended June 30, — Financial Summary ($ in thousands, except per share data)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – % Change | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – % Change | |
|---|---|---|---|---|---|---|
| Net Sales | 684,109 | 594,689 | 15.0% | 1,288,618 | 1,187,944 | 8.0% |
| Operating Income (Loss) | 37,210 | 17,965 | 107.0% | -12,412 | 46,253 | NM |
| Net Income (Loss) | 22,911 | 11,341 | 102.0% | -18,495 | 31,052 | NM |
| Earnings per Diluted Share | 1 | 0.5 | 100.0% | -0.81 | 1.36 | NM |
| Adjusted Net Income * | 27,052 | 11,952 | 126.0% | 37,365 | 31,262 | 20.0% |
| Adjusted Earnings per Diluted Share * | 1.18 | 0.52 | 127.0% | 1.63 | 1.37 | 19.0% |
Income Statement
Three Months Ended June 30, — Segment Results (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – % Change | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – % Change | ||
|---|---|---|---|---|---|---|---|
| Operating Income (Loss) | Surfactants | 34,362 | 13,367 | 157.0% | 52,910 | 42,297 | 25.0% |
| Operating Income (Loss) | Polymers | 22,469 | 17,159 | 31.0% | 31,291 | 25,177 | 24.0% |
| Operating Income (Loss) | Specialty Products | 5,007 | 5,258 | -5.0% | 9,722 | 10,766 | -10.0% |
| Operating Income (Loss) | Total Segment Operating Income | 61,838 | 35,784 | 73.0% | 93,923 | 78,240 | 20.0% |
| Operating Income (Loss) | Corporate Expenses | -24,628 | -17,819 | 38.0% | -106,335 | -31,987 | 232.0% |
| Operating Income (Loss) | Consolidated Operating Income (Loss) | 37,210 | 17,965 | 107.0% | -12,412 | 46,253 | NM |
Income Statement
Three Months Ended June 30, — (Unaudited – in 000’s, except per share data)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net Sales | 684,109 | 594,689 | 1,288,618 | 1,187,944 | |
| Cost of Sales | 584,127 | 522,804 | 1,123,785 | 1,040,596 | |
| Gross Profit | 99,982 | 71,885 | 164,833 | 147,348 | |
| Operating Expenses: | Selling | 14,866 | 14,657 | 27,032 | 26,765 |
| Operating Expenses: | Administrative | 24,203 | 22,801 | 45,516 | 44,215 |
| Operating Expenses: | Research, Development and Technical Services | 17,195 | 14,701 | 32,188 | 29,350 |
| Operating Expenses: | Deferred Compensation | 1,402 | 1,761 | 1,964 | 765 |
| Operating Expenses: | 57,666 | 53,920 | 106,700 | 101,095 | |
| Operating Expenses: | Business Restructuring | 5,106 | 70,545 | ||
| Operating Expenses: | Operating Income (Loss) | 37,210 | 17,965 | -12,412 | 46,253 |
| Other Income (Expense): | Interest, Net | -5,682 | -5,485 | -10,693 | -9,611 |
| Other Income (Expense): | Other, Net | 1,021 | 1,306 | 1,165 | 1,808 |
| Other Income (Expense): | ) | -4,661 | -4,179 | -9,528 | -7,803 |
| Other Income (Expense): | Income (Loss) Before Provision for Income Taxes | 32,549 | 13,786 | -21,940 | 38,450 |
| Other Income (Expense): | Provision for Income Taxes | 9,638 | 2,445 | -3,445 | 7,398 |
| Other Income (Expense): | Net Income (Loss) | 22,911 | 11,341 | -18,495 | 31,052 |
| Net Income (Loss) Per Common Share | Basic | 1 | 0.5 | -0.81 | 1.36 |
| Net Income (Loss) Per Common Share | Diluted | 1 | 0.5 | -0.81 | 1.36 |
| Shares Used to Compute Net Income Per Common Share | Basic | 22,897 | 22,865 | 22,893 | 22,866 |
| Shares Used to Compute Net Income Per Common Share | Diluted | 22,924 | 22,879 | 22,893 | 22,885 |
Income Statement
Three Months Ended June 30, — market prices of Company stock and the impact of deferred compensation on specific income statement line items is summarized below: (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Deferred Compensation | Operating Income (Expense) | -1,402 | -1,761 | -1,964 | -765 |
| Deferred Compensation | Other, net – Mutual Fund Gain | 1,334 | 1,669 | 1,268 | 1,299 |
| Deferred Compensation | Total Pre-Tax | -68 | -92 | -696 | 534 |
| Deferred Compensation | Total After-Tax | -52 | -69 | -529 | 401 |
Income Statement
Three Months Ended June 30, (in millions)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Change | Change Due to Foreign Currency Translation | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Change | Change Due to Foreign Currency Translation | |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 684.1 | 594.7 | 89.4 | 17.1 | 1,288.6 | 1,187.9 | 100.7 | 42.4 |
| Gross Profit | 100 | 71.9 | 28.1 | 2.9 | 164.8 | 147.3 | 17.5 | 5.4 |
| Operating Income (Loss) | 37.2 | 18 | 19.2 | 2.1 | -12.4 | 46.3 | -58.7 | 3.4 |
| Pretax Income (Loss) | 32.5 | 13.8 | 18.7 | 2.1 | -21.9 | 38.5 | -60.4 | 3.5 |
Income Statement
Three Months Ended June 30, 2026 — items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income. (in millions)
| Three Months Ended June 30, 2026 – Surfactants | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2026 – Polymers | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2026 – Specialty Products | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2026 – Unallocated Corporate | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2026 – Consolidated | Three Months Ended June 30, 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 34.4 | 22.5 | 5 | -24.6 | 37.2 | |||||
| Depreciation and Amortization | 20.5 | 8.7 | 1.5 | 0.2 | 30.9 | |||||
| Other, Net Income | 1 | 1 | ||||||||
| EBITDA | 69.1 | |||||||||
| Deferred Compensation | 0.1 | 0.1 | ||||||||
| Environmental Remediation | 0.1 | 0.1 | ||||||||
| Business Restructuring | 5.1 | 5.1 | ||||||||
| Adjusted EBITDA | 54.9 | 31.2 | 6.5 | -18.1 | 74.4 | |||||
| ($ in millions) | Unallocated Corporate | Consolidated | ||||||||
| Operating Income | 13.4 | 17.2 | 5.2 | -17.8 | 18 |
Income Statement
Six Months Ended June 30, 2026 — items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income. (in millions)
| Six Months Ended June 30, 2026 – Surfactants | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 – Polymers | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 – Specialty Products | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 – Unallocated Corporate | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 – Consolidated | Six Months Ended June 30, 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 52.9 | 31.3 | 9.7 | -106.3 | -12.4 | |||||
| Depreciation and Amortization | 43.1 | 17.3 | 2.9 | 0.6 | 63.9 | |||||
| Other, Net Income | 1.2 | 1.2 | ||||||||
| EBITDA | 52.7 | |||||||||
| Deferred Compensation | 0.7 | 0.7 | ||||||||
| Environmental Remediation | 0.2 | 0.2 | ||||||||
| Business Restructuring | 70.5 | 70.5 | ||||||||
| Adjusted EBITDA | 96 | 48.6 | 12.6 | -33.1 | 124.1 | |||||
| ($ in millions) | Unallocated Corporate | Consolidated | ||||||||
| Operating Income | 42.3 | 25.2 | 10.8 | -32 | 46.3 | |||||
| Depreciation and Amortization | 40.6 | 16.4 | 2.9 | 0.6 | 60.5 | |||||
| Other, Net Income | 1.8 | 1.8 | ||||||||
| EBITDA | 108.6 | |||||||||
| Deferred Compensation | -0.5 | -0.5 | ||||||||
| Environmental Remediation | 0.8 | 0.8 | ||||||||
| Adjusted EBITDA | 82.9 | 41.6 | 13.7 | -29.3 | 108.9 |
Balance Sheet
June 30, 2026 — June 30, 2026 and December 31, 2025
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| ASSETS | Current Assets | 974,764 | 858,959 |
| ASSETS | Property, Plant & Equipment, Net | 1,142,612 | 1,219,627 |
| ASSETS | Other Assets | 275,290 | 279,116 |
| ASSETS | Total Assets | 2,392,666 | 2,357,702 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Current Liabilities | 846,998 | 666,494 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Deferred Income Taxes | 10,998 | 11,450 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Long-term Debt | 244,069 | 340,975 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Other Non-current Liabilities | 78,555 | 94,773 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Total Stepan Company Stockholders’ Equity | 1,212,046 | 1,244,010 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Total Liabilities and Stockholders’ Equity | 2,392,666 | 2,357,702 |
Full release
(2) increased $23.0 million, or 45%, in the quarter. This increase was primarily due to higher Surfactant and Polymer earnings driven by sales volume growth and margin recovery.³
Outlook
“We believe we are positioned to continue delivering growth in all our key strategic businesses such as Crop Productivity, Oilfield, Tier 2/3 Surfactants and North American Polymers. We continue to execute on Project Catalyst, which is our comprehensive plan designed to further optimize our asset base and create a more productive and agile organization to enable balanced growth,” said Luis E. Rojo, President and Chief Executive Officer. “Despite the ongoing and significant market uncertainties and challenges, the organization is focused on executing our growth opportunities, productivity plans and cash interventions. With these actions and the strong first half results, we believe we will deliver full year Adjusted EBITDA growth, positive free cash flow and continue to de-leverage the balance sheet in 2026.”
Notes
(1)
Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.
(2)
EBITDA and adjusted EBITDA are non-GAAP measures. See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA.
(3)
Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures. Cash generated from operations was $8.4 million during the second quarter of
2026 and capital expenditures were $23.4 million.
Conference Call
Stepan Company will host a conference call to discuss its second quarter results at 9:00 a.m. ET (8:00 a.m. CT) on July 29, 2026. The call can be accessed by phone and webcast. To access the call by phone, please click on this
Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast can be accessed through the
Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.⁴
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com through the
Investors/Presentations page at approximately the same time as this press release is issued.
Corporate Profile
Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.
Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.
The Company’s common stock is traded on the New York Stock
Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com
More information about
Stepan’s sustainability program can be found on the Sustainability page at www.stepan.com
Contact: Ruben Velasquez.7-446-7500
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “guidance,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” “should,” “illustrative” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.
There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company’s control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan
Company’s Form
10-K,
Form
10-Q and Form
8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to our ability to realize cost savings or operating efficiencies associated with strategic initiatives, including Project Catalyst; accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws and other legal restrictions, including those relating to the international scope of our business; domestic and global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including changes in global trade policies, tariffs and retaliatory measures and countermeasures; currency exchange rate fluctuations; changes in tax policy and potential adverse tax consequences due to the international scope of our business;⁵ downgrades in our credit ratings or our ability to access the credit or capital markets if and when necessary; global political, military, security or other instability and increased security regulations; costs, delays and miscalculations in capacity needs related to expansion or other capital projects; interruption or breaches of information technology systems; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; our ability to retain executive management and key personnel; and issues relating to compliance with our debt covenants. In addition to the risks described in the Company’s periodic reports, the restructuring actions described herein may involve risks related to the execution of facility closures and asset decommissioning, potential operational disruptions, impacts on employees and local communities, environmental compliance, and the realization of anticipated cost savings and efficiencies.
These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.
* *
* * *
Tables follow⁶
Table I
STEPAN COMPANY
For the
Three and Six Months Ended June 30, 2026 and 2025
(Unaudited – in 000’s, except per share data)⁷
Table II
Reconciliation of
Non-GAAP
Net Income (Loss) and Earnings per Diluted Share*
The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company’s operating performance and financial condition. The Company uses this non-GAAP information as an indicator of business performance and evaluates management’s effectiveness with specific reference to these indicators. Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years. These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with
GAAP and may differ from similarly titled measures presented by other companies. The Company’s Annual Report on Form
10-K for the year ended December 31, 2025 contains additional information regarding the use of non-GAAP financial measures.
Summary of Second Quarter 2026 Adjusted Net Income Items
Adjusted net income excludes non-operational deferred compensation income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.⁸
Table III... (truntion of
Pre-Tax to
After-Tax
Adjustments
Management uses the non-GAAP adjusted net income metric to evaluate the Company’s operating performance.
Management excludes the items listed in the table below because they are non-operational items. The cumulative tax effect is typically calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.⁹
Table IV
Deferred Compensation Plans
The full effect of the deferred compensation plans on quarterly pre-tax income was $0.1 million of expense versus $0.1 million of expense in the prior year. The quarter-end market prices of Company stock and the impact of deferred compensation on specific income statement line items is summarized below:
Effects of Foreign Currency Translation
The Company’s foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. The table below presents the impact that foreign currency translation had on select income statement line items.
Corporate Expenses
Adjusted Corporate expenses increased $2.7 million, or 17% for the quarter. This increase was primarily due to higher incentive-based compensation expenses.¹⁰
Table V
Stepan Company
Consolidated Balance Sheets
June 30, 2026 and December 31, 2025
Selected Balance Sheet Information
The Company’s total debt decreased by $4.3 million and cash decreased by $27.1 million versus March 31, 2026. The Company’s net debt level increased $22.8 million versus March 31, 2026 and its net debt ratio was 31% versus 30% in the prior quarter (
Net Debt and
Net Debt Ratio are non-GAAP measures, reconciliations of which are shown in the table below). Management uses the non-GAAP net debt metric to show a more complete picture of the Company’s overall liquidity, financial flexibility and leverage level.
The major working capital components were:¹¹
Table VI
Reconciliations of
Non-GAAP
EBITDA and Adjusted EBITDA
Management uses the non-GAAP
EBITDA and adjusted EBITDA metrics to evaluate the Company’s operating performance.
Management excludes the items listed in the table below because they are non-operational items. Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income.¹²